We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Midatech Pharma plc (MTP) ADR Each Repr 100 Ord Spon

Sell:$1.33 Buy:$1.46 Change: No change
Market closed |  Prices as at close on 8 December 2021 | Switch to live prices |
Change: No change
Market closed |  Prices as at close on 8 December 2021 | Switch to live prices |
Change: No change
Market closed |  Prices as at close on 8 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Midatech Pharma PLC is a drug delivery technology company, which is focused on improving the bio-delivery and biodistribution of medicines. The Company has developed three in-house technology platforms, each with its own mechanism to improve delivery of medications to sites of disease. The Company's platform includes Q-Sphera platform, MidaSolve platform and MidaCore platform. Q-Sphera platform is a micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). MidaSolve platform is a nanotechnology used to dissolve insoluble drugs, which can be administered in liquid form directly and locally into tumors. MidaCore platform is a nanotechnology used for targeting medications to sites of disease. It has a pipeline of approximately 10 earlier stage programmes, which includes MTD211, MTD214, MTD220, MTX213, MTX214, MTX216, MTX110, MTX110, MTX110 and MTX114.

Contact details

Oddfellows Hse, 19 Newport Road
CF24 0AA
United Kingdom
+44 (1235) 841575

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$26.45 million
Shares in issue:
63.38 million
Great Britain
US dollar

Key personnel

  • Stephen Stamp
    Chief Executive Officer, Chief Financial Officer, Director
  • Steve Damment
    Executive Vice President - Research & Development
  • Dmitry Zamoryakhin
    Chief Scientific Officer
  • Kelly Conlon
    Vice President - Translational Medicine
  • Paul Seaman
    Vice President - Pharmaceutical & Technology Development
  • Sam Barker
    Director of Business Development
  • Nitu Sharma
    Senior Project Manager
  • Fiona Sharp
    Group Financial Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.